Health
3 Reasons to Buy Moderna Now – Motley Fool
The shares have surged in the triple digits since the start of the year. And additional gains may be on the horizon.
Moderna(NASDAQ:MRNA) has taken center stage in the race to develop a coronavirus vaccine. In March, the clinical-stage biotech company became the first to bring a vaccine into human trials. Since then, management has reported encouraging trial data that allowed it to move on to phase 3 studies — a final and crucial step before regulatory approval. Since the start of the year, the shares have surged by 297%.
Some investors may wonder if, considering the share gains, there is any steam left. Of …
Continue Reading
